CO-ADMINISTRATION OF THE ACC INHIBITOR PF-05221304 AND THE DGAT2 INHIBITOR PF-06865571 IS SAFE AND WELL TOLERATED IN SHORT-TERM STUDIES IN NON-HUMAN PRIMATES AND HUMANS WITH NO CLINICALLY MEANINGFUL PHARMACOKINETIC INTERACTION